Life science 2026: the new rules of capital

A more selective investment climate, higher expectations for proven value, and longer exit paths are reshaping the landscape for life sciences companies. In 2026, access to capital is no longer merely a matter of financing; it has become a strategic competitive factor that determines which innovations reach patients and the market.